SWITCHING FROM INFLIXIMAB ORIGINATOR TO A BIOSIMILAR DOES NOT AFFECT PHARMACOKINETICS, IMMUNOGENICITY AND EFFICACY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
van Hoeve, Karen
Dreesen, Erwin
Hoffman, Ilse
Ferrante, Marc
Ann, Gils
Vermeire, Severine
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
879
引用
收藏
页码：S199 / S199
页数：1
相关论文
共 50 条
  • [21] Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients
    Eberl, Anja
    Huoponen, Saara
    Pahikkala, Tapio
    Blom, Marja
    Arkkila, Perttu
    Sipponen, Taina
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (12) : 1348 - 1353
  • [22] EFFICACY AND SAFETY OF SWITCHING FROM REFERENCE INFLIXIMAB TO BIOSIMILAR INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: FIRST FRENCH EXPERIENCE
    Soret, Pierre-Antoine
    Prieux-Klotz, Caroline
    Avouac, Jerome
    Molto, Anna
    Dior, Marie
    Brieau, Bertrand
    Dreanic, Johann
    Camus, Marine
    Barret, Maximilien
    Coriat, Romain
    Conort, Ornella
    Chast, FranOois
    Goulvestre, Claire
    Le Jeunne, Claire
    Dougados, Maxime
    Nahon, Stephane
    Chaussade, Stanislas
    Abitbol, Vered
    GASTROENTEROLOGY, 2017, 152 (05) : S402 - S402
  • [23] The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
    Dutt, Krishneel
    Srinivasan, Ashish
    Van Langenberg, Daniel
    BIODRUGS, 2022, 36 (05) : 639 - 644
  • [24] Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experience
    Soret, P. -A.
    Prieux-Klotz, C.
    Avouac, J.
    Molto, A.
    Dior, M.
    Brieau, B.
    Dreanic, J.
    Camus, M.
    Barret, M.
    Coriat, R.
    Conort, O.
    Chast, F.
    Goulvestre, C.
    Le Jeunne, C.
    Dougados, M.
    Nahon, S.
    Chaussade, S.
    Abitbol, V.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S318 - S319
  • [25] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study
    Haifer, Craig
    Srinivasan, Ashish
    An, Yoon-Kyo
    Picardo, Sherman
    van Langenberg, Daniel
    Menon, Shankar
    Begun, Jakob
    Ghaly, Simon
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 214 (03) : 128 - +
  • [26] The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
    Krishneel Dutt
    Ashish Srinivasan
    Daniel Van Langenberg
    BioDrugs, 2022, 36 : 639 - 644
  • [27] Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study
    Fischer, S.
    Mesfin, S.
    Klenske, E.
    Schmitt, H.
    Vitali, F.
    Hirschmann, S.
    Ramming, A.
    Zundler, S.
    Rath, T.
    Krebs, S.
    Doerje, F.
    Uter, W.
    Nagore, D.
    Meyer, S.
    Neurath, M. F.
    Atreya, R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S466 - S467
  • [28] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [29] Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
    Martinez-Feito, Ana
    Bravo-Gallego, Luz Yadira
    Hernandez-Breijo, Borja
    Diez, Jesus
    Garcia-Ramirez, Laura
    Jaquotot, Marta
    Plasencia-Rodriguez, Chamaida
    Nozal, Pilar
    Mezcua, Araceli
    Martin- Arranz, Maria Dolores
    Pascual-Salcedo, Dora
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [30] Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
    Ana Martínez-Feito
    Luz Yadira Bravo-Gallego
    Borja Hernández-Breijo
    Jesús Diez
    Laura García-Ramirez
    Marta Jaquotot
    Chamaida Plasencia-Rodríguez
    Pilar Nozal
    Araceli Mezcua
    María Dolores Martín- Arranz
    Dora Pascual-Salcedo
    Scientific Reports, 10
12345